Skip to content
God Of Sound – Lifestyle
Author:
Actinogen Medical
Actinogen XanaMIA pivotal Alzheimer’s disease trial completes final patient visit, with topline results on track for November
September 23, 2026
Xanamem proof-of-concept trial demonstrating anti-depressant activity published in the British Journal of Psychiatry
July 20, 2026
Actinogen receives positive EMA scientific advice aligned with prior FDA guidance for its Alzheimer’s disease program
May 28, 2026
Actinogen commences open-label phase of XanaMIA Alzheimer’s trial and provides business update
April 1, 2026